Actinium (225Ac) rhPSMA-10.1

Phase 2

EARTH LIFE SCIENCES INC (CLTS)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

5 competitors in Metastatic Castration-resistant Prostate Cancer

ATNMATNM-400

LLY[Lu-177]-PNT2002

Phase 3

XNCRvudalimab monotherapy

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer

Clinical Trial

NCT07414940

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CLTS

EARTH LIFE SCIENCES INC

Services-Detective, Guard & Armored Car Services•North America•NASDAQ

Related Pipeline

18F-Labeled Positron Emission Tomography (PET) Diagnostic AgentPhase 3

Prostate Cancer

18F fluciclovinePhase 3

Brain Metastases

18F-Fluciclovine PET CTPhase 3

Cancer of the Prostate

rhPSMA-7.3 (18F) InjectionPhase 3

Prostate Cancer

Lutetium (177Lu) rhPSMA-10.1 InjectionPhase 2

Prostate Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts